• SPX
  • $5,728.80
  • 0.41 %
  • $23.35
  • DJI
  • $42,052.19
  • 0.69 %
  • $288.73
  • N225
  • $38,053.67
  • -2.63 %
  • -$1,027.58
  • FTSE
  • $8,177.15
  • 0.83 %
  • $67.05
  • IXIC
  • $18,239.92
  • 0.8 %
  • $144.77
SCYNEXIS, Inc. (SCYX) Stock Price, News & Analysis

SCYNEXIS, Inc. (SCYX) Stock Price, News & Analysis

Currency in USD Disclaimer

$1.34

-$0.02

(-1.48%)

Day's range
$1.33
Day's range
$1.38
50-day range
$1.26
Day's range
$1.73
  • Country: US
  • ISIN: US8112922005
52 wk range
$1.26
Day's range
$3.07
  • CEO: Dr. David Gonzalez Angulo M.D.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -4.90
  • Piotroski Score 3.00
  • Grade Overweight
  • Symbol (SCYX)
  • Company SCYNEXIS, Inc.
  • Price $1.34
  • Changes Percentage (-1.48%)
  • Change -$0.02
  • Day Low $1.33
  • Day High $1.38
  • Year High $3.07

SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 11/10/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $0.00
  • High Stock Price Target $0.00
  • Low Stock Price Target $0.00
  • Potential Upside/Downside N/A
  • Consensus Rating Strong Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) $2.11
  • Trailing P/E Ratio 1.05
  • Forward P/E Ratio 1.05
  • P/E Growth 1.05
  • Net Income $67.04 M

Income Statement

Quarterly

Annual

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.